Opaleye Management, Inc. and Related Parties File Schedule 13G for Larimar Therapeutics, Inc.

Opaleye Management, Inc., Opaleye, L.P., and James Silverman have jointly filed a Schedule 13G amendment with the SEC, disclosing their beneficial ownership of 4,110,000 shares of common stock in Larimar Therapeutics, Inc., representing 4.80% of the company's outstanding shares. The filing is voluntary and indicates that the shares are not held for the purpose of influencing the control of the issuer. The filing is made under Rule 13d-1(c) and includes a Joint Filing Agreement among the reporting persons. The shares are held by Opaleye, L.P., with Opaleye Management, Inc. serving as the investment adviser and James Silverman exercising control over the adviser.